Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer buff.ly/3ptuso6
Lundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs" buff.ly/3ohxGvu $LUN.co
Dicerna CEO explains how a desire to expand collaborations turned into a potential acquisition buff.ly/3nMSpXP $DRNA $NOVO $NVO
Nykode Therapeutics CEO after another million-dollar deal: We have no competitors buff.ly/3oPSRDW $REGN
Novo Nordisk Foundation's CEO warns antibiotic resistance will be world's second-biggest killer buff.ly/30Wcq5B #AMR
Grass allergy sufferers wanted for Lundbeck phase I antibody study buff.ly/30UL2Vp $LUN.co
Pharmacosmos sees big potential in million-dollar acquisition buff.ly/3kKX0Yo
Positive CHMP opinion paves way for Lundbeck's Vyepti in Europe buff.ly/3C3RrKA $LUN.co
European interest in Wegovy expected to match US demand, says EVP at Novo Nordisk buff.ly/3wGqb3V $NOVO $NVO
Novo Nordisk within touching distance of European obesity market as CHMP recommends approval buff.ly/3ooCq0Z $NVO $NOVO
ALK upgrades guidance after positive Q3 report buff.ly/3F9KBVZ $ALK
Lundbeck lets 300 employees go: "We are on a constant hunt to make our organization as effective as possible" buff.ly/3D4RXcv $LUN.co
Novo Nordisk objects to proposed reimbursement change for its fast-acting insulin in Denmark buff.ly/3kpdoh5 $NOVO $NVO




















